JuventeWith PGX expected to reach the decision point for mass industrialization in Q3 2024 with the commisioning of the 100L scale-up the potential for Juvente has never been stronger. CZO has also produced a preservative-free dry powder formulation of oat beta glucan that is being evaluated by Symrise and is strengthening claims for avenanthramide and beta glucan with the Angiogenesis Foundation. A dry powder formulaton of avenanthramide is also being developed. Previously CZO also won an industry award for its Juvente-PGX/CoQ10. Gilles has said that Symrise likes what CZO is doing with PGX and mentioned as a possibility PGX-CoQ10 as a second-generation Aveeno.
PGX has been seen as the real differentiator for Juvente and with PGX expected to reach the decision point for mass industrialization this year here's what was previously said at the Society of Cosmetic Chemists.
------------
Paul Moquin, Ph.D., Ceapro’s Director of Scientific Affairs and New Business Development, presented the poster titled, “PGX Technology: a disruptive green platform technology to generate tuneable nanoporous water-soluble biopolymer delivery systems for bioactives,” at the Society of Cosmetic Chemists’ 72nd Annual Scientific Meeting & Technology Showcase being held this week in New York, NY.
“Using our proprietary PGX technology, the Company has conducted research on various biopolymer samples from different sources. Given the unique properties obtained with processed compounds and especially the increased surface area allowing for inclusion of other biomaterial, PGX becomes an extraordinary and unique enabling technology to produce innovative delivery systems. We expect PGX to be a game-changing technology and are pleased to participate at this scientific and partnering event within the cosmeceutical industry,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.
The Company’s Pressurized Gas eXpanded (PGX)Technology, which is patented in the U.S., Europe and Canada, is a platform technology that is used to convert biopolymers into high-value materials overcoming the challenges associated with the drying of high molecular weight biopolymers using conventional technologies.
Ceapro is developing its PGX enabling technology at various scale levels for all industries and all applications. The Company’s PGX technology is a novel spray drying technique for processing water-soluble biopolymers and can produce numerous morphologies of biopolymers ranging from fine fibers to granular powder, which are highly water soluble. As an example, the Company successfully developed a new water-soluble chemical complex composed of Co-Enzyme Q10 and beta glucan (iBG). This impregnated beta glucan has the potential for use in cosmeceuticals, nutraceuticals and functional food and drinks.
“By showcasing iBG at this partnering meeting in cosmeceuticals, Ceapro is targeting several markets to bring energy back to aging skin, repair structural skin components in depth, especially burn victims, and provide long lasting hydration to decrease fine lines and wrinkles while improving skin health. However, we believe that iBG is just the beginning for Ceapro as our disruptive PGX technology has continued to show potential in its ability to dry numerous biopolymers or proteins and impregnate the resulting structure with a myriad of other bioactives. With this capability, we believe that Ceapro will be able to generate unique customized cosmetic ingredients and delivery systems aligned with customers’ needs,” concluded Mr. Gagnon.